BioSpace News Archive

Drug Development

Pharma Two B Ltd. Release: First Patients Dosed in Phase III Multi-Center, Multinational Study to Determine the Efficacy, Safety and Tolerability of P2B001 in Patients with Early Stage Parkinson’s Disease

“This fundraising enables Pharma Two B to complete the Phase III and expand its pipeline.”

February 6, 2018

·

2 min read

Biotech Bay

Univfy Scores $6M Series A to Expand Predictive IVF Platform

The funding round was led by led by Rethink Impact.

February 6, 2018

·

4 min read

Genetown

Allurion Technologies Commences Landmark Pivotal U.S. Clinical Trial for the Elipse Balloon

Allurion Technologies today announces the start of ENLIGHTEN, a United States clinical trial for the Elipse Balloon – the world’s first and only procedureless™ gastric balloon for weight loss.

February 6, 2018

·

3 min read

Deals

Texas A&M Institute for Regenerative Medicine and Celltex Therapeutics Enter Agreement for Alzheimer’s Research

The announcement signals the first year of a multi-year research study investigating potential therapies for Alzheimer’s disease using autologous mesenchymal stem cell (MSC)-derived exosomes.

February 6, 2018

·

4 min read

Business

PharmaCyte Announces Completion of Preparatory Work and Commencement of Testing by Eurofins of Cells from Its Master Cell Bank

PharmaCyte today announced that the steps necessary for the testing of cells from its Master Cell Bank (MCB) have been completed by Eurofins Lancaster Laboratories and that testing began last month.

February 6, 2018

·

4 min read

Genetown

Sysmex America Expands Use of ThingWorx Platform to Transform the Patient Experience

PTC and Sysmex America today announced that Sysmex has expanded its use of the ThingWorx® Industrial Innovation Platform to enable Sysmex to revolutionize the delivery of blood test results with the Sysmex XW-100™ automated hematology CBC analyzer.

February 6, 2018

·

4 min read

OncoQuest Completes US$6 Million Private Placement

The financing was led by a South Korean institutional fund. Under the private placement, the Company issued 603,000 common shares at US$10.00 share.

February 6, 2018

·

3 min read

FDA

Grifols HyperRAB (rabies immune globulin [human]) 300 IU/mL Receives FDA Approval to Treat Patients Exposed to Rabies Virus Infection

The most common adverse reactions during clinical trials were injection-site pain and headache.

February 6, 2018

·

8 min read

Genetown

New Japan Study Finds Clinicians Make Significantly Fewer Mistakes When Using UpToDate from Wolters Kluwer

Physicians who used UpToDate had a significantly lower rate of diagnostic errors compared with a control group without UpToDate (2 percent versus 24 percent).

February 6, 2018

·

3 min read

Business

Spectralytics Opens Facility Dedicated to New Product Development

Spectralytics announces the opening of a product development center in Maple Plain, Minn. Building upon its reputation of high-quality laser processing solutions for medical device manufacturing,

February 6, 2018

·

3 min read